EP0928194A4 - Zusammensetzungen und verfahren zur verabreichung von antagonisten des integrin-rezeptors - Google Patents

Zusammensetzungen und verfahren zur verabreichung von antagonisten des integrin-rezeptors

Info

Publication number
EP0928194A4
EP0928194A4 EP97938565A EP97938565A EP0928194A4 EP 0928194 A4 EP0928194 A4 EP 0928194A4 EP 97938565 A EP97938565 A EP 97938565A EP 97938565 A EP97938565 A EP 97938565A EP 0928194 A4 EP0928194 A4 EP 0928194A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
receptor antagonists
integrin receptor
administering integrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97938565A
Other languages
English (en)
French (fr)
Other versions
EP0928194A1 (de
Inventor
Michael F Sugrue
Robert J Gould
George D Hartman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9619583.9A external-priority patent/GB9619583D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0928194A1 publication Critical patent/EP0928194A1/de
Publication of EP0928194A4 publication Critical patent/EP0928194A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP97938565A 1996-08-29 1997-08-25 Zusammensetzungen und verfahren zur verabreichung von antagonisten des integrin-rezeptors Withdrawn EP0928194A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2580896P 1996-08-29 1996-08-29
US25808P 1996-08-29
GBGB9619583.9A GB9619583D0 (en) 1996-09-19 1996-09-19 Compositions and methods for administering integrin receptor antagonists
GB9619583 1996-09-19
PCT/US1997/014908 WO1998008518A1 (en) 1996-08-29 1997-08-25 Compositions and methods for administering integrin receptor antagonists

Publications (2)

Publication Number Publication Date
EP0928194A1 EP0928194A1 (de) 1999-07-14
EP0928194A4 true EP0928194A4 (de) 2001-01-17

Family

ID=26310068

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97938565A Withdrawn EP0928194A4 (de) 1996-08-29 1997-08-25 Zusammensetzungen und verfahren zur verabreichung von antagonisten des integrin-rezeptors

Country Status (5)

Country Link
EP (1) EP0928194A4 (de)
JP (1) JP2001501597A (de)
AU (1) AU729488B2 (de)
CA (1) CA2263998A1 (de)
WO (1) WO1998008518A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067972A1 (en) * 2001-02-28 2002-09-06 Duke University Method of inducing vitreous detachment
JP2007005582A (ja) 2005-06-24 2007-01-11 Asm Japan Kk 基板搬送装置及びそれを搭載した半導体基板製造装置

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0645376A1 (de) * 1993-09-23 1995-03-29 MERCK PATENT GmbH Substituierte 1-Phenyl-oxazolidin-2-on Derivate deren Herstellung und der Verwendung als Adhäsionsrezeptor-Antagonisten
WO1996000574A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1997044333A1 (de) * 1996-05-17 1997-11-27 Merck Patent Gmbh 1,2,4-oxadiazole as adhäsionsrezeptor-antagonisten

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229366A (en) * 1990-10-23 1993-07-20 Fuji Photo Film Co., Ltd. Peptide-containing polyethylene glycol derivatives and application thereof
JPH06502643A (ja) * 1990-11-01 1994-03-24 スミスクライン・ビーチャム・コーポレイション フィブリノーゲン拮抗剤としてのγ−ターンペプチド模倣化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0645376A1 (de) * 1993-09-23 1995-03-29 MERCK PATENT GmbH Substituierte 1-Phenyl-oxazolidin-2-on Derivate deren Herstellung und der Verwendung als Adhäsionsrezeptor-Antagonisten
WO1996000574A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1997044333A1 (de) * 1996-05-17 1997-11-27 Merck Patent Gmbh 1,2,4-oxadiazole as adhäsionsrezeptor-antagonisten

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
H P HAMMES ET AL: "Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization", NATURE MEDICINE,US,NATURE PUBLISHING, CO, vol. 2, no. 5, May 1996 (1996-05-01), pages 529 - 533, XP002138522, ISSN: 1078-8956 *
See also references of WO9808518A1 *

Also Published As

Publication number Publication date
JP2001501597A (ja) 2001-02-06
AU4086297A (en) 1998-03-19
WO1998008518A1 (en) 1998-03-05
EP0928194A1 (de) 1999-07-14
CA2263998A1 (en) 1998-03-05
AU729488B2 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
EP0934305A4 (de) Integrinantagonisten
EP1047425A4 (de) Integrinrezeptor antagonisten
IL118325A0 (en) Integrin receptor antagonists and pharmaceutical compositions containing them
CY2576B1 (en) Vitronectin receptor antagonists
ZA953311B (en) Non-peptidyl tachykinin receptor antagonists
HU9603525D0 (en) Vironectin receptor antagonists
IL122641A0 (en) Vitronectin receptor antagonists their preparation and their use
EP0946164A4 (de) Integrin antagonisten
SI0838217T1 (en) Cosmetic composition containing neuropeptide Y receptor antagonist
EP0912175A4 (de) Antagonisten des fibrinogenrezeptors
EP1007051A4 (de) Integrin rezeptor antagonisten
EP0880511A4 (de) Integrin-rezeptor-antagonisten
EP0885205A4 (de) Fibrinogen-rezeptor-antagonisten
AU2020497A (en) Receptor and transporter antagonists
EP0885213A4 (de) Fibrinogenrezeptor antagonisten
IL135797A (en) Thrombin receptor antagonists and pharmaceutical compositions comprising them
IL122643A0 (en) Vitronectin receptor antagonists their preparation and their use
EP1027337A4 (de) Integrin-rezeptor-antagonisten
HUP0002929A3 (en) 2-acylaminopropanamines as tachykinin receptor antagonists and pharmaceutical compositions containing the same
GB9820014D0 (en) Receptor antagonists and uses thereof
HUP0003548A3 (en) 2-acylaminopropanamines as tachykinin receptor antagonists and pharmaceutical compositions containing the same
AU3935897A (en) B1-bradykinin receptor antagonists and use thereof
EP0928194A4 (de) Zusammensetzungen und verfahren zur verabreichung von antagonisten des integrin-rezeptors
GB9619583D0 (en) Compositions and methods for administering integrin receptor antagonists
IL119820A0 (en) Integrin receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990329

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20001204

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20020507

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020918